Stephanie Crumpton, NP
Nurse Practitioner · Danville, VANPI 1629321146
Payments from drug & device makers
Across 210 payments — averaging $16.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$324
- Pfizer$255
- Novartis$253
- Johnson & Johnson$210
- Novo Nordisk$207
- Boehringer Ingelheim$198
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,413100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 21 | $324 |
| Pfizer | 19 | $255 |
| Novartis | 13 | $253 |
| Johnson & Johnson | 13 | $210 |
| Novo Nordisk | 14 | $207 |
| Boehringer Ingelheim | 11 | $198 |
| Corcept Therapeutics | 9 | $195 |
| AstraZeneca | 10 | $181 |
| Lilly USA, LLC | 10 | $178 |
| Dexcom, Inc. | 7 | $113 |
| Bayer | 8 | $113 |
| Merck | 7 | $108 |
| Esperion Therapeutics, Inc. | 7 | $107 |
| GSK | 5 | $80 |
| AbbVie | 4 | $75 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $74 |
| Mylan Specialty L.p. | 5 | $67 |
| Sanofi-aventis U.S. LLC | 5 | $63 |
| Biogen | 4 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $57 |
| Amarin Pharma, Inc. | 4 | $57 |
| Currax Pharmaceuticals LLC | 4 | $56 |
| Inspire Medical Systems, Inc. | 1 | $54 |
| Xeris Pharmaceuticals, Inc. | 3 | $44 |
| Exact Sciences | 2 | $36 |
| Aimmune Therapeutics, Inc. | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Sumitomo Pharma America, Inc. | 2 | $29 |
| Shield Therapeutics Inc | 1 | $20 |
| Insulet Corporation | 1 | $20 |
| Abbott | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Alkermes, Inc. | 1 | $16 |
| Viatris Specialty LLC | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Seqirus USA Inc | 1 | $13 |
How this compares
$3,427 in reported general payments places this provider in the 90th percentile of 2,166 nurse practitioner providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 121 | $135,504 |
| TrulicityDulaglutide | 86 | $119,412 |
| EliquisApixaban | 109 | $103,052 |
| JanuviaSitagliptin Phosphate | 84 | $100,353 |
| OzempicSemaglutide | 64 | $82,460 |
| JardianceEmpagliflozin | 64 | $80,714 |
| MounjaroTirzepatide | 48 | $73,190 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 47 | $73,128 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $47,360 |
| XareltoRivaroxaban | 45 | $47,140 |
| RybelsusSemaglutide | 26 | $32,838 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $22,964 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $19,633 |
| MyrbetriqMirabegron | 34 | $17,318 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $17,054 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $178 | $192,602134 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $181 | $158,469155 claims |
| Novo NordiskOzempic, Rybelsus | $207 | $115,29890 claims |
| PfizerEliquis | $255 | $103,052109 claims |
| MerckJanuvia | $108 | $100,35384 claims |
| Boehringer IngelheimJardiance, Tradjenta | $198 | $89,71777 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $63 | $73,12847 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $80 | $66,99370 claims |
| Johnson & JohnsonXarelto | $210 | $47,14045 claims |
| NovartisEntresto | $253 | $8,00112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,166 nurse practitioner providers in Virginia.
Other nurse practitioner in Danville
- Kim NesterDanville$8K
- Samantha FoxGate City$207K
- Mikel GrayCharlottesville$174K
- Kevin BrigleRichmond$166K
- Denese GomesRichmond$126K
- Ashley CarmenAlexandria$99K
- Rachel AndersonCharlottesville$90K
- Megan FrancisArlington$81K
- Elizabeth WilletteNorfolk$58K
- Lacey LyleSuffolk$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.